Presence of prostacyclin receptor in arteriosclerotic human femoral artery. 2006

A Muto, and Y Kondo, and Y Yamamoto, and H Yamada, and O Washimi, and Y Miyauchi, and F Kudo, and A Dardik, and T Nishibe
Department of Surgery, Division of Cardiovascular Surgery, Fujita Health University, Toyoake, Japan.

OBJECTIVE Prostacyclin, which is mainly synthesized by vascular endothelial cells, exerts antiplatelet and smooth-muscle-relaxant effects, thereby maintaining cardiovascular homeostasis. Prostacyclin analogues have been clinically proven to improve ischemic symptoms and prevent the occurrence of vascular events in the lower extremities of patients with arteriosclerosis obliterans. We examined the presence of prostacyclin receptor (IP receptor) in an arteriosclerotic human femoral artery. METHODS Specimens of the femoral artery were obtained at the time of limb amputation from an 83-year-old woman. Atherosclerotic lesions and associated changes such as calcification were evident. The specimens were stained with hematoxylin and eosin, and processed for immunohistochemistry. RESULTS A monolayer of cells was observed on the luminal side of the femoral artery. Single immunohistochemistry showed the presence of the IP receptors on cells of the luminal side of the femoral artery. Triple-immunofluorescence staining revealed colocalization of IP-receptor-positive cells and cells positive for von Willebrand factor, a marker of vascular endothelial cells. CONCLUSIONS We investigated the presence of the IP receptor in the human femoral artery immunohistochemically, and demonstrated their strong expression in endothelial cells. This finding suggests that prostacyclin or prostacyclin analogues may act on their receptors on endothelial cells in patients with arteriosclerosis obliterans.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D005260 Female Females
D005263 Femoral Artery The main artery of the thigh, a continuation of the external iliac artery. Common Femoral Artery,Arteries, Common Femoral,Arteries, Femoral,Artery, Common Femoral,Artery, Femoral,Common Femoral Arteries,Femoral Arteries,Femoral Arteries, Common,Femoral Artery, Common
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D044006 Receptors, Epoprostenol Cell surface receptors for EPOPROSTENOL. They are coupled to HETEROTRIMERIC G-PROTEINS. PGI2 Receptor,Prostacyclin Receptor,Receptors, Prostacyclin,PGI2 Receptors,Prostaglandin I2 Receptors,Prostaglandins X Receptors,Receptor, Prostaglandin I2,Epoprostenol Receptors,Prostacyclin Receptors,Prostaglandin I2 Receptor,Receptor, PGI2,Receptor, Prostacyclin,Receptors, PGI2,Receptors, Prostaglandin I2,Receptors, Prostaglandins X
D050197 Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA. Atherogenesis,Atherogeneses,Atheroscleroses

Related Publications

A Muto, and Y Kondo, and Y Yamamoto, and H Yamada, and O Washimi, and Y Miyauchi, and F Kudo, and A Dardik, and T Nishibe
December 1977, Canadian Medical Association journal,
A Muto, and Y Kondo, and Y Yamamoto, and H Yamada, and O Washimi, and Y Miyauchi, and F Kudo, and A Dardik, and T Nishibe
April 1980, Archives of surgery (Chicago, Ill. : 1960),
A Muto, and Y Kondo, and Y Yamamoto, and H Yamada, and O Washimi, and Y Miyauchi, and F Kudo, and A Dardik, and T Nishibe
August 1997, The Journal of cardiovascular surgery,
A Muto, and Y Kondo, and Y Yamamoto, and H Yamada, and O Washimi, and Y Miyauchi, and F Kudo, and A Dardik, and T Nishibe
June 2018, The Journal of pharmacology and experimental therapeutics,
A Muto, and Y Kondo, and Y Yamamoto, and H Yamada, and O Washimi, and Y Miyauchi, and F Kudo, and A Dardik, and T Nishibe
January 2002, Vitamins and hormones,
A Muto, and Y Kondo, and Y Yamamoto, and H Yamada, and O Washimi, and Y Miyauchi, and F Kudo, and A Dardik, and T Nishibe
January 1992, Agents and actions. Supplements,
A Muto, and Y Kondo, and Y Yamamoto, and H Yamada, and O Washimi, and Y Miyauchi, and F Kudo, and A Dardik, and T Nishibe
January 1979, Khirurgiia,
A Muto, and Y Kondo, and Y Yamamoto, and H Yamada, and O Washimi, and Y Miyauchi, and F Kudo, and A Dardik, and T Nishibe
January 1988, Biomedica biochimica acta,
A Muto, and Y Kondo, and Y Yamamoto, and H Yamada, and O Washimi, and Y Miyauchi, and F Kudo, and A Dardik, and T Nishibe
January 1961, Surgery,
A Muto, and Y Kondo, and Y Yamamoto, and H Yamada, and O Washimi, and Y Miyauchi, and F Kudo, and A Dardik, and T Nishibe
June 1977, Revista do Hospital das Clinicas,
Copied contents to your clipboard!